FertiProt
Gel Formulation for Fertility Enhancement
Health Tech & Life Sciences
Non Active, Jan 2022 ceased to operate
Company Overview
Snapshot
Founded in October 2011 by Ronen Shemesh, PhD, FertiProt operated with 1–10 employees. The company ceased operations in January 2022.
Business overview
FertiProt developed an innovative technology focused on enhancing fertility through formulated proteins. Its core product, available as a gel or suppository, aimed to increase the possibility of fertilization for couples with fertility impairment. The company's approach sought to reduce the need for invasive hormonal treatments like IVF by improving the efficacy of artificial insemination or natural intercourse. FertiProt operated within the Health Tech & Life Sciences sector, specifically targeting the Pharmaceuticals and Medical Biotechnology markets.
Log in to access full profile ›Company Intelligence Q&A
- What is FertiProt's primary offering?
- FertiProt developed a gel formulation designed to enhance fertility by utilizing formulated proteins to increase the possibility of fertilization.
- When was FertiProt founded?
- FertiProt was founded in October 2011.
- Who founded FertiProt?
- FertiProt was founded by Ronen Shemesh, PhD.
- What problem did FertiProt aim to solve?
- FertiProt aimed to address fertility impairment by offering a non-invasive solution that could potentially reduce the need for hormonal-based treatments like IVF, increasing conception probability for couples.
- What is the current status of FertiProt?
- FertiProt ceased to operate in January 2022.